Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab With Acalabrutinib in Relapsed/Refractory Mantle Cell Lymphoma
NCT06054776Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by City of Hope. Started Dec 2024; status: recruiting.
02
Drugs
glofitamabacalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06054776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054776.